个人简历
顾杨卓，男，汉，四川大学生物治疗全国重点实验室博士毕业，四川大学华西医院博士后。在Signal Transduction and Targeted Therapy、Chinese Chemical Letters、Acta Pharmacologica Sinica、Medcomm、Journal of Translational Medicine、Scientific Reports等刊物以第一作者或共同第一作者发表论文数篇。
教学工作
研究领域
RNA介导的免疫治疗和基因治疗、基因和小分子药物的纳米递送。
代表性论文
1.Yangzhuo Gu, Jingyun Yang, Cai He, Tingmei Zhao, Ran Lu, et al. Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases. Signal Transduction and Targeted Therapy, 2023, 8(1): 273.
2.Wen Xiao#, Fazhan Wang#, Yangzhuo Gu#, Xi He#, Na Fan, et al. PEG400-mediated nanocarriers improve the delivery and therapeutic efficiency of mRNA tumor vaccines. Chinese Chemical Letters, 2023: 108755. (online)
3.Yangzhuo Gu, Jiangyao Duan, Na Yang, Yuxin Yang, Xing Zhao，mRNA vaccines in the prevention and treatment of diseases, MedComm, 2022, 3(3): e167.
4.Shiqi Long#, Yangzhuo Gu#, Yuanyuan An, Xiaojin Lin, Xiaoqing Chen, et al. Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway, Journal of Translational Medicine, 2021, 19(1): 1-14.
5.YangZhuo Gu, Xing Zhao, XiangRong Song，Ex vivo pulsed dendritic cell vaccination against cancer, Acta Pharmacologica Sinica, 2020, 41(7): 959-969.
6.YangZhuo Gu#, ChuanWen Fan#, Ran Lu, Bin Shao, YaXiong Sang, et al. Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity, Scientific Reports, 2016, 6(1): 32351.
主持或主研课题
1.针对新冠病毒SARS-CoV-2的mRNA疫苗的效力、安全性和作用机制研究，中国博士后科学基金(特别资助），主持，已结题。
2.靶向E6/E7的宫颈癌mRNA疫苗的mRNA制备研究，横向技术开发委托，主持，已结题。
社会兼职
Acta Pharmacologica Sinica、 Scientific Reports、 Naunyn-Schmiedeberg’s Archives of Pharmacology等杂志审稿人
